CARE downgrades Orchid Pharma’s long-term bank facilities to BBB+ with a stable outlook and adjusts related ratings, citing FY25 performance and ongoing amalgamation/asset acquisition processes as key factors.
AI Assistant
Orchid Pharma Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.